Granted Patent
B2
US 12,365,726 · App. 18/134,095 · Granted Jul 22, 2025
Anti-VEGF antibody constructs
Inventors:
Emmanuel John Simons (Brookline, MA); Robert Ng (Newton, MA); Michael McKenna (Boston, MA)
Assignee:
Akouos, Inc.
C07K16/22A61K48/0066A61P27/16C07K14/005C07K14/55C12N15/86C07K2317/24C07K2317/55C07K2317/76C12N2750/14143C12N2750/14152
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides a construct comprising a coding sequence operably linked to a promoter, wherein the coding sequence encodes a vascular endothelial growth factor (VEGF) binding agent or a portion thereof. In some embodiments, a construct is an AAV construct. In some embodiments, an AAV construct is a part of an AAV particle. Compositions comprising constructs and AAV particles described herein can be useful in treating hearing loss, for example, hearing loss associated with vestibular schwannoma.
Claims (14)
1. An adeno-associated virus (AAV) particle comprising: (i) a nucleic acid construct that comprises the nucleotide sequence set forth in SEQ ID NO: 91, and (ii) an AAV Anc80 capsid.
2. The AAV particle of claim 1 , wherein the AAV Anc80 capsid is an AAV Anc80L65 capsid.
3. The AAV particle of claim 1 , wherein the AAV Anc80 capsid comprises the amino acid sequence set forth in SEQ ID NO: 113.
4. A kit comprising the AAV particle of claim 1 .
5. A composition comprising the AAV particle of claim 1 .
6. A pharmaceutical composition comprising a composition comprising the AAV particle of claim 1 and a pharmaceutically acceptable carrier.
7. The AAV particle of claim 1 , wherein the AAV Anc80 capsid comprises the amino acid sequence set forth in SEQ ID NO: 114.
8. An adeno-associated virus (AAV) particle comprising: (i) a nucleic acid construct that comprises the nucleotide sequence set forth in SEQ ID NO: 92, and (ii) an AAV Anc80 capsid.
9. The AAV particle of claim 8 , wherein the AAV Anc80 capsid is an AAV Anc80L65 capsid.
10. The AAV particle of claim 8 , wherein the AAV Anc80 capsid comprises the amino acid sequence set forth in SEQ ID NO: 113.
11. A kit comprising the AAV particle of claim 8 .
12. A composition comprising the AAV particle of claim 8 .
13. A pharmaceutical composition comprising a composition comprising the AAV particle of claim 8 and a pharmaceutically acceptable carrier.
14. The AAV particle of claim 8 , wherein the AAV Anc80 capsid comprises the amino acid sequence set forth in SEQ ID NO: 114.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 28, 2023
From: SIMONS, EMMANUEL JOHN; NG, ROBERT; MCKENNA, MICHAEL
To: AKOUOS, INC.
Reel/Frame 064092/0300 →
Continuity (4)
Continuation
PCTUS2021061205
· Nov 30, 2021
Provisional Application
63152832
· Feb 23, 2021
Provisional Application
63120189
· Dec 1, 2020
References Cited (400)
US 4797368A
· Carter et al.
· 1989
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 5122458A
· Post et al.
· 1992
[cited by applicant]
US 5139941A
· Muzyczka et al.
· 1992
[cited by applicant]
US 5168062A
· Stinski
· 1992
[cited by applicant]
US 5478745A
· Samulski et al.
· 1995
[cited by applicant]
US 5741683A
· Zhou et al.
· 1998
[cited by applicant]
US 5952221A
· Kurtzman et al.
· 1999
[cited by applicant]
US 6001650A
· Colosi
· 1999
[cited by applicant]
US 6054297A
· Carter et al.
· 2000
[cited by applicant]
US 6057152A
· Samulski et al.
· 2000
[cited by applicant]
US 6156303A
· Russell et al.
· 2000
[cited by applicant]
US 6204059B1
· Samulski et al.
· 2001
[cited by applicant]
US 6268213B1
· Samulski et al.
· 2001
[cited by applicant]
US 6407213B1
· Carter et al.
· 2002
[cited by applicant]
US 6491907B1
· Rabinowitz et al.
· 2002
[cited by applicant]
US 6660514B1
· Zolotukhin et al.
· 2003
[cited by applicant]
US 6884879B1
· Baca et al.
· 2005
[cited by applicant]
US 6951753B2
· Shenk et al.
· 2005
[cited by applicant]
US 7060269B1
· Baca et al.
· 2006
[cited by applicant]
US 7094604B2
· Snyder et al.
· 2006
[cited by applicant]
US 7169901B2
· Baca et al.
· 2007
[cited by applicant]
US 7172893B2
· Rabinowitz et al.
· 2007
[cited by applicant]
US 7201898B2
· Monahan et al.
· 2007
[cited by applicant]
US 7229823B2
· Samulski et al.
· 2007
[cited by applicant]
US 7282199B2
· Gao et al.
· 2007
[cited by applicant]
US 7297334B2
· Baca et al.
· 2007
[cited by applicant]
US 7365166B2
· Baca et al.
· 2008
[cited by applicant]
US 7439065B2
· Ferrari et al.
· 2008
[cited by applicant]
US 7485291B2
· Fang et al.
· 2009
[cited by applicant]
US 7498024B2
· Fang et al.
· 2009
[cited by applicant]
US 7588772B2
· Kay et al.
· 2009
[cited by applicant]
US 7612181B2
· Wu et al.
· 2009
[cited by applicant]
US 7662623B2
· Fang et al.
· 2010
[cited by applicant]
US 7709224B2
· Fang et al.
· 2010
[cited by applicant]
US 7714119B2
· Fang et al.
· 2010
[cited by applicant]
US 7790449B2
· Gao et al.
· 2010
[cited by applicant]
US 8258268B2
· Wu et al.
· 2012
[cited by applicant]
US 8513390B2
· Stagliano et al.
· 2013
[cited by applicant]
US 8586714B2
· Ghayur et al.
· 2013
[cited by applicant]
US 8716450B2
· Ghayur et al.
· 2014
[cited by applicant]
US 8722855B2
· Ghayur et al.
· 2014
[cited by applicant]
US 8735546B2
· Ghayur et al.
· 2014
[cited by applicant]
US 8822645B2
· Ghayur et al.
· 2014
[cited by applicant]
US 8962804B2
· Williams et al.
· 2015
[cited by applicant]
US 9079953B2
· Harding et al.
· 2015
[cited by applicant]
US 9453241B2
· Pan
· 2016
[cited by applicant]
US 9522949B2
· Fang et al.
· 2016
[cited by applicant]
US 20010034062A1
· Koenig
· 2001
[cited by applicant]
US 20060018882A1
· Kaemmerer et al.
· 2006
[cited by applicant]
US 20060040354A1
· O'Keefe
· 2006
[cited by applicant]
US 20060110364A1
· Harding
· 2006
[cited by applicant]
US 20070141029A1
· Brough
· 2007
[cited by applicant]
US 20090215178A1
· Tang
· 2009
[cited by applicant]
US 20100317096A1
· Fang et al.
· 2010
[cited by applicant]
US 20110052576A1
· Ferrara et al.
· 2011
[cited by applicant]
US 20110065779A1
· Fang et al.
· 2011
[cited by applicant]
US 20130078260A1
· Cheeseman et al.
· 2013
[cited by applicant]
US 20130090375A1
· Crystal et al.
· 2013
[cited by applicant]
US 20150147317A1
· Robblee et al.
· 2015
[cited by applicant]
US 20150182638A1
· Crystal et al.
· 2015
[cited by applicant]
US 20170321214A1
· Zhang et al.
· 2017
[cited by applicant]
US 20180311319A1
· Constable et al.
· 2018
[cited by applicant]
US 20190060328A1
· Ibañez et al.
· 2019
[cited by applicant]
US 20190060425A1
· Scheel et al.
· 2019
[cited by applicant]
US 20190127455A1
· Simpson et al.
· 2019
[cited by applicant]
US 20190211091A1
· Simpson et al.
· 2019
[cited by applicant]
US 20200277364A1
· Yoo et al.
· 2020
[cited by applicant]
US 20210071149A1
· Simons et al.
· 2021
[cited by applicant]
US 20220143221A1
· Danos et al.
· 2022
[cited by applicant]
US 20220195462A1
· Danos et al.
· 2022
[cited by applicant]
US 20220280608A1
· Pakola et al.
· 2022
[cited by applicant]
US 20220288236A1
· Burns et al.
· 2022
[cited by applicant]
US 20220288238A1
· Tretiakova et al.
· 2022
[cited by applicant]
US 20230057380A1
· Gao et al.
· 2023
[cited by applicant]
US 20230057519A1
· Simpson et al.
· 2023
[cited by applicant]
US 20230075045A1
· Wang et al.
· 2023
[cited by applicant]
US 20230295243A1
· Shi et al.
· 2023
[cited by applicant]
US 20230372538A1
· Bee et al.
· 2023
[cited by applicant]
US 20230414788A1
· Bee et al.
· 2023
[cited by applicant]
US 20240024508A1
· Bee et al.
· 2024
[cited by applicant]
US 20240335560A1
· Kirn et al.
· 2024
[cited by applicant]
US 20240343791A1
· Dong et al.
· 2024
[cited by applicant]
US 20250136673A1
· Simons et al.
· 2025
[cited by applicant]
CN 102219859A
· 2011
[cited by applicant]
CN 103143017A
· 2013
[cited by applicant]
CN 103492574A
· 2014
[cited by applicant]
CN 104994882A
· 2015
[cited by applicant]
CN 106414487A
· 2017
[cited by applicant]
CN 107074969A
· 2017
[cited by applicant]
EP 2101807B1
· 2016
[cited by applicant]
JP 2017510297A
· 2017
[cited by applicant]
WO WO92022653A1
· 1992
[cited by applicant]
WO WO96037234A1
· 1996
[cited by applicant]
WO WO9709442A1
· 1997
[cited by examiner]
WO WO9810088A1
· 1998
[cited by applicant]
WO WO9845331A2
· 1998
[cited by applicant]
WO WO00028004A1
· 2000
[cited by applicant]
WO WO01059142A1
· 2001
[cited by applicant]
WO WO2003042397A2
· 2003
[cited by applicant]
WO WO2004113493A2
· 2004
[cited by applicant]
WO WO2005017149A1
· 2005
[cited by applicant]
WO WO2005033321A2
· 2005
[cited by applicant]
WO WO05073384A2
· 2005
[cited by applicant]
WO WO0612414A2
· 2006
[cited by applicant]
WO WO2006017325A2
· 2006
[cited by applicant]
WO WO2006110689A2
· 2006
[cited by applicant]
WO WO2008077077A2
· 2008
[cited by applicant]
WO WO2011104307A2
· 2011
[cited by applicant]
WO WO2012115980A1
· 2012
[cited by applicant]
WO WO2013173129A2
· 2013
[cited by applicant]
WO WO2014043480A1
· 2014
[cited by applicant]
WO WO2014178078A2
· 2014
[cited by applicant]
WO WO2015054653A2
· 2015
[cited by examiner]
WO WO2015123715A1
· 2015
[cited by applicant]
WO WO2015138616A1
· 2015
[cited by applicant]
WO WO2015142963A1
· 2015
[cited by applicant]
WO WO2016040441A1
· 2016
[cited by applicant]
WO WO2017040528A1
· 2017
[cited by applicant]
WO WO2017050825A1
· 2017
[cited by applicant]
WO WO2017075119A1
· 2017
[cited by applicant]
WO WO2017100791A1
· 2017
[cited by applicant]
WO WO2017117464A1
· 2017
[cited by applicant]
WO WO2017147265A1
· 2017
[cited by applicant]
WO WO2017180936A1
· 2017
[cited by applicant]
WO WO2017181021A1
· 2017
[cited by applicant]
WO WO2017218974A2
· 2017
[cited by applicant]
WO WO2017218981A2
· 2017
[cited by applicant]
WO WO2019067540A1
· 2019
[cited by applicant]
WO WO2019079496A2
· 2019
[cited by applicant]
WO WO2019104279A1
· 2019
[cited by applicant]
WO WO2019116349A1
· 2019
[cited by applicant]
WO WO2019126329A1
· 2019
[cited by examiner]
WO WO2019164854A1
· 2019
[cited by applicant]
WO WO2020097372A1
· 2020
[cited by examiner]
WO WO2020206098A1
· 2020
[cited by applicant]
WO WO2020219868A1
· 2020
[cited by applicant]
WO WO2021046245A1
· 2021
[cited by applicant]
WO WO2021071835A1
· 2021
[cited by applicant]
WO WO2021076794A1
· 2021
[cited by applicant]
WO WO2021108530A1
· 2021
[cited by applicant]
WO WO2021231808A2
· 2021
[cited by applicant]
WO WO2021255589A1
· 2021
[cited by applicant]
WO WO2021255590A1
· 2021
[cited by applicant]
WO WO2022018516A1
· 2022
[cited by applicant]
WO WO2022051537A1
· 2022
[cited by applicant]
WO WO2022076549A1
· 2022
[cited by applicant]
WO WO2022076591A1
· 2022
[cited by applicant]
WO WO2022076595A1
· 2022
[cited by applicant]
WO WO2022119839A1
· 2022
[cited by applicant]
WO WO2022240778A1
· 2022
[cited by applicant]
WO WO2023280157A1
· 2023
[cited by applicant]
WO WO2023284879A1
· 2023
[cited by applicant]
WO WO2023150142A1
· 2023
[cited by applicant]
WO WO2023155918A1
· 2023
[cited by applicant]
WO WO2024002076A1
· 2024
[cited by applicant]
WO WO2024222934A1
· 2024
[cited by applicant]
Landegger et al Nature Biotechnoloby, 35(3), 280-284 (Year: 2017).
[cited by examiner]
Wu et al Journal of Molecular Biology, 294, 151-162, (Year: 1999).
[cited by examiner]
Maccallum et al (Journal of Molecular Biology, 262, pp. 732-745 (Year: 1996).
[cited by examiner]
Skolnick et al Trends in Biotechnology vol. 18, pp. 34-39 (Year: 2000).
[cited by examiner]
Casset et al Biochemical and Biophysical Research Communications vol. 307, pp. 198-205 (Year: 2003).
[cited by examiner]
Vajdos et al Journal of Molecular Biology vol. 320, pp. 415-428 (Year: 2002).
[cited by examiner]
Zinn Cell Rep. 12(6): 1056-1068 (Year: 2015).
[cited by examiner]
Suzuki Scientific Reports, 7: 45524, 1-11 (Year: 2017).
[cited by examiner]
Chen (Microorganisms 12, 310, 1-16 (Year: 2024).
[cited by examiner]
Earley Human Gene Therapy, 31, 2, 151-162 (Year: 2020).
[cited by examiner]
Adachi, K. et al., Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing, Nat Commun., 5:3075 (2014).
[cited by applicant]
Ahn, S. et al., Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes,
[cited by applicant]
Akil, O. et al., Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model,
[cited by applicant]
Akil, O. et al., Restoration of hearing in the VGLUT3 knockout mouse using virally mediated gene therapy,
[cited by applicant]
Al-Moyed, H. et al., A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice,
[cited by applicant]
Andersen, J. et al., Herpesvirus-Mediated Gene Delivery into the Rat Brain: Specificity and Efficiency of the Neuron-Specific Enolase Promoter, Cell Mol. Neurobiol., 13(5):503-515 (1993).
[cited by applicant]
Andres-Mateos, E. et al., Optimized surgical approach leads to highly efficient AAV gene transfer to inner hair cells in rhesus macaque,
[cited by applicant]
Ansari, S. et al., Surgery for vestibular schwannomas: a systematic review of complications by approach,
[cited by applicant]
Arbuthnot, P et al., In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector, Hum Gene Ther., 7(13):1503-1514 (1996).
[cited by applicant]
Askew, C. et al., Tmc gene therapy restores auditory function in deaf mice,
[cited by applicant]
Asokan, A. et al., The AAV Vector Toolkit: Poised at the Clinical Crossroads, Molecular Therapy, 20(4):699-708 (2012).
[cited by applicant]
AveXis. 2019. Zolgensma US prescribing information. US Food and Drug Administration. https://www.fda.gov/media/126109/download. Accessed Aug. 31, 2020.
[cited by applicant]
Bakri, S. J. et al., Pharmacokinetics of Intravitreal Ranibizumab (Lucentis), American Academy of Ophthalmology, 14(12):2179-2182 (2007).
[cited by applicant]
Banaszynski, L. A. et al., A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules, Cell, 126(5): 995-1004 (2012).
[cited by applicant]
Bankoti, K. et al., Advances and challenges in adeno-associated viral inner-ear gene therapy for sensorineural hearing loss, Molecular Therapy: Methods & Clinical Development, 21:209-236 (2021).
[cited by applicant]
Bartoli. M. et al., Noninvasive Monitoring of Therapeutic Gene Transfer in Animal Models of Muscular Dystrophies, Gene Ther. 13:20-28 (2006).
[cited by applicant]
Batt, D. and Carmichael, G., Characterization of the polyomavirus late polyadenylation signal, Mol Cell Biol., 15(9):4783-4790 (1995).
[cited by applicant]
Batt, D. B. and Carmichael, G. G., Characterization of the polyomavirus late polyadenylation signal, Mol. Cell Biol., 15(9):4783-4790 (1995).
[cited by applicant]
Bennett, J. et al., AAV2 gene therapy readministration in three adults with congenital blindness,
[cited by applicant]
Bohne, B. and Harding, G., Degeneration in the cochlea after noise damage: primary versus secondary events, Am J Otol., 21(4):505-509 (2000).
[cited by applicant]
Bonne, N. et al., An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth,
[cited by applicant]
Boshart, M. et al., A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus, Cell, 41(2):521-530 (1985).
[cited by applicant]
Brastianos, P. and Batchelor, T., VEGF inhibitors in brain tumors, Clin Adv Hematol Oncol., 7(11):753-768 (2009).
[cited by applicant]
Bulankina, A. and Moser, T., Neural circuit development in the mammalian cochlea,
[cited by applicant]
Carlson, M. et al., A cross-sectional survey of the North American Skull Base Society: current practice patterns of vestibular schwannoma evaluation and management in North America,
[cited by applicant]
Carlson, M. et al., Long-term quality of life in patients with vestibular schwannoma: an international multicenter cross-sectional study comparing microsurgery, stereotactic radiosurgery, observation, and nontumor contr…
[cited by applicant]
Carneiro, A. et al., Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab,
[cited by applicant]
Carvalho, L. et al., Synthetic adeno-associated viral vector efficiently targets mouse and nonhuman primate retina in vivo,
[cited by applicant]
Casset, F. et al., A peptide mimetic of an anti-CD4 monoclonal antibody by rational design, Biochem. Biophys. Res. Commun., 307(1):198-205 (2003).
[cited by applicant]
Caye-Thomasen, P. et al. Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate,
[cited by applicant]
Caye-Thomasen, P. et al., VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate,
[cited by applicant]
Chamney, S. et al., A mutation in the Norrie disease gene (NDP) associated with familial exudative vitreoretinopathy, Eye, 25(12):1658 (2011).
[cited by applicant]
Chen, C. et al., mRNA decay mediated by two distinct AU-rich elements from c-fos and granulocyte-macrophage colony-stimulating factor transcripts: different deadenylation kinetics and uncoupling from translation, Mol Ce…
[cited by applicant]
Chen, H. and Cleck, J., Adverse effects of anticancer agents that target the VEGF pathway, Nat Rev Clin Oncol., 6(8):465-477 (2009).
[cited by applicant]
Chen, J. et al., A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma,
[cited by applicant]
Chen, J. et al., Expression of rat bone sialoprotein promoter in transgenic mice, J Bone Miner Res., 11(5):654-664 (1996).
[cited by applicant]
Chen, Q. et al., An AU-rich element in the 3′ untranslated region of the spinach chloroplast petD gene participates in sequence-specific RNA-protein complex formation, Mol Cell Biol., 15(4):2010-2018 (1995).
[cited by applicant]
Chen, X. et al., HSV amplicon-mediated neurotrophin-3 expression protects murine spiral ganglion neurons from cisplatin-induced damage,
[cited by applicant]
Chen, Y. et al., Selection and Analysis of an Optimized Anti-VEGF Anitbody: Crystal Structure of an Affinity-matured Fab in Complex and Antigen, J. Mol. Biol., 293:865-881 (1999).
[cited by applicant]
Chien, W. et al., Gene therapy restores hair cell stereocilia morphology in inner ears of deaf whirler mice,
[cited by applicant]
Christoforidis, J. et al., PET/CT imaging of I-124-radiolabeled bevacizumab and ranibizumab after intravitreal injection in a rabbit model,
[cited by applicant]
Clinicaltrials.gov. 2020a. NCT02132130: Safety, Tolerability and Efficacy for CGF166 in Patients with Unilateral or Bilateral Severe-to-profound Hearing Loss. National Institutes of Health. Accessed Aug. 31, 2020.
[cited by applicant]
Clinicaltrials.gov. 2020b. NCT03066258: RGX-314 gene therapy for neovascular AMD trial. National Institutes of Health. Accessed Aug. 31, 2020.
[cited by applicant]
Clinicaltrials.gov. 2020c. NCT03748784: ADVM-022 Intravitreal Gene Therapy for Wet AMD (Optic). National Institutes of Health. Accessed Aug. 31, 2020.
[cited by applicant]
Clinicaltrials.gov. 2020d. NCT04418427: ADVM-022 Intravitreal Gene Therapy for DME (Infinity). National Institutes of Health. Accessed Aug. 31, 2020.
[cited by applicant]
Colella, P. et al., Emerging issues in AAV-mediated in vivo gene therapy, Mol Ther Methods Clin Dev., 8:87-104 (2018).
[cited by applicant]
Cotten, M. et al., High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles, P.N.A.S. …
[cited by applicant]
Cromie, K. et al., Nanobodies and their use in GPCR Drug Discovery, Curr. Top. Med. Chem., 15:2543-2557 (2016).
[cited by applicant]
Curiel, D. T., High-efficiency gene transfer employing adenovirus-polylysine-DNA complexes, Nat Immun., 13(2-3):141-64 (1994).
[cited by applicant]
Dai, C. et la., Rhesus cochlear and vestibular functions are preserved after inner ear injection of saline volume sufficient for gene therapy delivery,
[cited by applicant]
De Felipe, P. and Izqierdo, M., Tricistronic and tetracistronic retroviral vectors for gene transfer, Hum Gene Ther, 11(13):1921-1931 (2000).
[cited by applicant]
De Felipe, P. et al., Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy, Gene Ther., 6(2):198-208 (1999).
[cited by applicant]
De Fougerolles, A., Delivery vehicles for small interfering RNA in vivo, Hum Gene Ther., 19(2):125-132 (2008).
[cited by applicant]
De Genst, E. et al., Antibody repertoire development in camelids, Dev Comp Immunol., 30(1-2):187-198 (2006).
[cited by applicant]
De Meyer., T. et al., Nanobody-based products as research and diagnostic tools, Trends Biotechnol., 32(5):263-270 (2014).
[cited by applicant]
Digiammarino, E. et al., Design and generation of DVD-Ig™ molecules for dual-specific targeting, Methods Mol Biol., 899:145-156 (2012).
[cited by applicant]
Dilwali, S. et al., Secreted factors from human vestibular schwannomas can cause cochlear damage,
[cited by applicant]
Dinh, C. et al., A xenograft model of vestibular schwannoma and hearing loss,
[cited by applicant]
Dmitriev, I. et al., An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism, J Virol., 72(12):970…
[cited by applicant]
Doherty, J. and Friedman, R., Controversies in building a management algorithm for vestibular schwannomas,
[cited by applicant]
Failla, C. et al., Positive and Negative Regulation of Angiogenesis by Soluble Vascular Endothelial Growth Factor Receptor-1, Int J Mol Sci., 19(5):1306 (2018).
[cited by applicant]
Fath, S. et al., Multiparameter RNA and Codon Optimization: A Stardardized Tool to Access and Enhance Autologous Mammalian Gene Expression, PLoS One, 6(3):e17596, 14 pages (2011).
[cited by applicant]
FDA, Applying human factors and usability engineering to medical devices—guidance for industry and Food and Drug Administration staff. In, edited by Food and Drug Administration and Center for Devices and Radiological H…
[cited by applicant]
FDA, Design and analysis of shedding studies for virus or bacteria-based gene therapy and oncolytic products—guidance for industry. In, edited by Food and Drug Administration and Center for Biologics Evaluation and Rese…
[cited by applicant]
FDA, Evaluation of devices used with Regenerative Medicine Advanced Therapies—guidance for industry. In, edited by Food and Drug Administration, Center for Biologics Evaluation and Research, Center for Devices and Radio…
[cited by applicant]
FDA, Principles of premarket pathways for combination products guidance for industry and FDA staff—draft guidance. In, edited by Food and Drug Administration, Office of Combination Products, Center for Biologics Evaluat…
[cited by applicant]
FDA, Use of International Standard ISO 10993-1, “Biological evaluation of medical devices—Part 1: Evaluation and testing within a risk management process”—guidance for industry and Food and Drug Administration staff. In…
[cited by applicant]
Ferrara, N. et al., Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy, Biochem Biophys Res Commun., 333(2):328-335 (2005).
[cited by applicant]
Fisher, K. et al., Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis, J Virol., 70(1):520-532 (1996).
[cited by applicant]
Flotte, T. et al., A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease,
[cited by applicant]
Flotte, Terence R., Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy,
[cited by applicant]
Francis, S. et al., The adeno-associated viral Anc80 vector efficiently transduces inner ear cells in cynomolgus macaques (
[cited by applicant]
Fujioka, M. et al., Inflammatory and immune responses in the cochlea: potential therapeutic targets for sensorineural hearing loss, Front Pharmacol., 5:287 (2014).
[cited by applicant]
Furler, S. et al., Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neurons, Gene Ther., 8(11):864-8…
[cited by applicant]
Gaffen, S.L. and Liu, K.D., Overview of interleukin-2 function, production and clinical applications, Cytokine, 28:109-123 (2004).
[cited by applicant]
Gao, G. et al., Clades of Adeno-associated viruses are widely disseminated in human tissues, J. Virol.. 78(12): 6381-6388 (2004).
[cited by applicant]
Gao, X. et al., Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model,
[cited by applicant]
Gao, Y. et al., The adeno-associated viral AAVAnc80 vector efficiently transduces inner ear cells in olive baboons (
[cited by applicant]
Garber, K., Bispecific antibodies rise again, Nat Rev Drug Discov., 13(11):799-801 (2014).
[cited by applicant]
Gaudreault, J. et al., Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration, Invest Ophthalmol Vis Sci., 46(2):726-733 (2005).
[cited by applicant]
Gehlhausen, J. et al., A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation,
[cited by applicant]
Genentech. 2017. Lucentis US prescribing information. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125156s114lbl.pdf., 7 pages, Accessed Aug. 31, 2020.
[cited by applicant]
Giovannini, M. et al., Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2,
[cited by applicant]
Giovannini, M. et al., Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein,
[cited by applicant]
Glasscock, M. et al., Twenty-five years of experience with stapedectomy, Laryngoscope, 105(9 Pt 1): 899-904 (1995).
[cited by applicant]
Golfinos, J. et al., A matched cohort comparison of clinical outcomes following microsurgical resection or stereotactic radiosurgery for patients with small- and medium-sized vestibular schwannomas,
[cited by applicant]
Gossen, M. and Bujard, H., Tight control of gene expression in mammalian cells by tetracycline-responsive promoters, Proc Natl Acad Sci USA, 89(12):5547-5551 (1992).
[cited by applicant]
Gossen, M. et al., Transcriptional activation by tetracyclines in mammalian cells, Science, 268(5218):1766-1769 (1995).
[cited by applicant]
Gutmann, D. and Giovannini, M., Mouse models of neurofibromatosis 1 and 2,
[cited by applicant]
Gyorgy, B. et al., Gene transfer with AAV9-PHP.B rescues hearing in a mouse model of Usher Syndrome 3A and transduces hair cells in a non-human primate, Mol Ther Methods Clin Dev., 13:1-13 (2019).
[cited by applicant]
Halpin, C et al., Self-processing 2A-polyproteins—a system for co-ordinate expression of multiple proteins in transgenic plants, Plant J., 17(4):453-45 (1999).
[cited by applicant]
Hamernik, R. et al., Anatomical correlates of impulse noise-induced mechanical damage in the cochlea,
[cited by applicant]
Hanna, R. et al., Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence,
[cited by applicant]
Hansal, S. et al., Induction of antigen-specific hyporesponsiveness by transplantation of hemopoietic cells containing an MHC class I transgene regulated by a lymphocyte-specific promoter, J Immunol., 161(3):1063-1068 (…
[cited by applicant]
Harvey, D. and Caskey, C., Inducible control of gene expression: prospects for gene therapy, Curr Opin Chem Biol., 2(4):512-518 (1998).
[cited by applicant]
Haryadi, R. et al., Optimization of Heavy Chain and Light Chain Signal Peptides for High Level Expression of Therapeutic Antibodies in CHO Cells, PLOS One, 16 pages (2015).
[cited by applicant]
Heidel, J. et al., Aministration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA, Proc Natl Acad Sci USA, 104(14):5715-5721 (2007).
[cited by applicant]
Hellen, C. and Sarnow, P., Internal ribosome entry sites in eukaryotic mRNA molecules, Genes Dev., 15(13):1593-1612 (2001).
[cited by applicant]
Huang, V. et al., Improvement in patient-reported hearing after treatment with bevacizumab in people with neurofibromatosis type 2,
[cited by applicant]
Huang, X. et al., Spontaneous tumour shrinkage in 1261 observed patients with sporadic vestibular schwannoma,
[cited by applicant]
Hudry, E. et al., Efficient gene transfer to the central nervous system by single-stranded Anc80L65,
[cited by applicant]
Hu-Lieskovan, S. et al., Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma, Cancer Res., 65(19):8984-89…
[cited by applicant]
Husseman, J. and Raphael, Y., Gene Therapy in the Inner Ear Using Adenovirus Vectors, Adv. Otorhinolaryngol., 66:37-51 (2009).
[cited by applicant]
Hutton-Smith, L. et al., A mechanistic model of the intravitreal pharmacokinetics of large molecules and the pharmacodynamic suppression of ocular vascular endothelial growth factor levels by ranibizumab in patients wit…
[cited by applicant]
Ikeda, Y. et al., Efficient gene transfer to kidney mesenchymal cells using a synthetic adeno-associated viral vector,
[cited by applicant]
International Search Report for PCT/US2018/066512 (AAV-Mediated Delivery of Therapeutic Antibodies to the Inner Ear, filed Dec. 19, 2018), received from ISA/KR, 7 pages (Apr. 17, 2019).
[cited by applicant]
International Search Report for PCT/US2021/061205, 6 pages (Mar. 31, 2022).
[cited by applicant]
Isgrig, K. et al., AAV2.7m8 is a powerful viral vector for inner ear gene therapy, Nat. Commun., 10(1):427 (2019).
[cited by applicant]
Ito, T. et al., SLC26A4 mutation testing for hearing loss associated with enlargement of the vestibular aqueduct, World J. Otorhinolaryngol., 3(2):26-34 (2013).
[cited by applicant]
Iwamoto, M. et al., A general chemical method to regulate protein stability in the mammalian central nervous system. Chem Biol., 17(9): 981-988 (2010).
[cited by applicant]
Jakob, C. et al., Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule, Mabs, (3):358-363 (2013).
[cited by applicant]
Jung, J. et al., Secretion of soluble vascular endothelial growth factor receptor 1 (sVEGFR1/sFlt1) requires Arf1, Arf6, and Rab11 GTPases, PLoS One, 7(9):e44572, 11 pages (2012).
[cited by applicant]
Kanaan, N. M. et al., Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS, Mol. Ther. Nucleic Acids, 8:184-197 (2017).
[cited by applicant]
Kapurch, J. et al., Temporal lobe gliosarcoma after gamma knife radiosurgery for vestibular schwannoma,
[cited by applicant]
Karajannis, M. et al., Sustained imaging response and hearing preservation with low-dose bevacizumab in sporadic vestibular schwannoma,
[cited by applicant]
Karch-Georges, A. et al., MRI of endolymphatic hydrops in patients with vestibular schwannomas: a case-controlled study using non-enhanced T2-weighted images at 3 Teslas,
[cited by applicant]
Kaul, V. and Cosetti, M., Management of vestibular schwannoma (including NF2): facial nerve considerations,
[cited by applicant]
Kelleher, Z. T. and Vos, J. M., Long-term episomal gene delivery in human lymphoid cells using human and avian adenoviral-assisted transfection, Biotechniques, 17(6):1110-17 (1994).
[cited by applicant]
Kendall, R. et al,. Identification of a Natural Soluble Form of the Vascular Endothelial Growth Factor Receptor, FLT-1, and its Heterodimerization with KDR, Biochem Biophys Res Commun. 226:324-328 (1996).
[cited by applicant]
Kendall., R. and Thomas, K., Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor, Proc Natl Acad Sci USA, 90(22):10705-10709 (1993).
[cited by applicant]
Kijanka, M. et al., Nanobody-based cancer therapy of solid tumors, Nanomedicine (Lond)., 10(1):161-174 (2015).
[cited by applicant]
Killeen, D. et al., Long-term effects of bevacizumab on vestibular schwannoma volume in neurofibromatosis type 2 patients,
[cited by applicant]
Kim, H. et al., FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye,
[cited by applicant]
Kim, M. et al., Methionine sulfoxide reductase B3-targeted in utero gene therapy rescues hearing function in a mouse model of congenital sensorineural hearing loss,
[cited by applicant]
Kim, M. et al., Targeted gene delivery into the mammalian inner ear using synthetic serotypes of adeno-associated virus vectors,
[cited by applicant]
Kirchmann, M. et al., Ten-year follow-up on tumor growth and hearing in patients observed with an intracanalicular vestibular schwannoma,
[cited by applicant]
Klettner, A. and Roider, J., Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways,
[cited by applicant]
Klump, H. et al., Retroviral vector-mediated expression of HoxB4 in hematopoietic cells using a novel coexpression strategy, Gene Ther., 8(10):811-817 (2001).
[cited by applicant]
Koen, N. et al., Location of small intracanalicular vestibular schwannomas based on magnetic resonance imaging,
[cited by applicant]
Kondziolka, D. et al., The newly diagnosed vestibular schwannoma: radiosurgery, resection, or observation?,
[cited by applicant]
Konishi, T. et al., Effects of chemical alteration in the endolymph on the cochlear potentials,
[cited by applicant]
Koutsimpelas, D. et al., Expression of vascular endothelial growth factor and basic fibroblast growth factor in sporadic vestibular schwannomas correlates to growth characteristics,
[cited by applicant]
Koutsimpelas, D. et al., The VEGF/VEGF-R axis in sporadic vestibular schwannomas correlates with irradiation and disease recurrence,
[cited by applicant]
Kovaleva, M. et al., Shark variable new antigen receptor biologics—a novel technology platform for therapeutic drug development, Expert Opin Biol Ther., 14(10):1527-1539 (2014).
[cited by applicant]
Krah, S. et al., Single-domain antibodies for biomedical applications, Immunopharmacol Immunotoxicol., 38(1):21-28 (2016).
[cited by applicant]
Kshettry, V. et al., Incidence of vestibular schwannomas in the United States,
[cited by applicant]
Kujawa, S. and Liberman, M. et al., Synaptopathy in the noise-exposed and aging cochlea: Primary neural degeneration in acquired sensorineural hearing loss, Hear Res., 330(Pt B):191-199 (2015).
[cited by applicant]
Landegger, L. et al., A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear,
[cited by applicant]
Leabman, M. et al., Effects of altered Fc?R binding on antibody pharmacokinetics in cynomolgus monkeys, Mabs, 5(6):896-903 (2013).
[cited by applicant]
Lees, K. et al., Natural history of sporadic vestibular schwannoma: a volumetric study of tumor growth,
[cited by applicant]
Levitt, N. et al., Definition of an efficient synthetic poly(A) site, Genes Dev., 3(7):1019-1025 (1989).
[cited by applicant]
Li, S. et al., Effective electrophoretic mobilities and charges of anti-VEGF proteins determined by capillary zone electrophoresis,
[cited by applicant]
Li, W. et al., Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles, Mol. Ther. 16(7):1252-1260 (2008).
[cited by applicant]
Lichtenbeld, H. et al., Effect of local anti-VEGF antibody treatment on tumor microvessel permeability,
[cited by applicant]
Litovsky, Ruth, Development of the auditory system,
[cited by applicant]
Littman, T. et al., The quinoxalinediones DNOX, CNOX and two related congeners suppress hair cell-to-auditory nerve transmission,
[cited by applicant]
Liu, H. et al., Current strategies for drug delivery to the inner ear, Acta Pharmaceutica Sinica B, 3(2):86-96 (2013).
[cited by applicant]
Liu, Y. et al., AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration, Molecular Therapy, 26(2):542-549 (2017).
[cited by applicant]
Liu, Y. et al., Promoter effects of adeno-associated viral vector for transgene expression in the cochlea in vivo, Experimental and Molecular Medicine, 39(2):170-175 (2007).
[cited by applicant]
London, N.R. et al., The role of vascular endothelial growth factor and vascular stability in diseases of the ear, The Laryngoscope, 124:E340-E346 (2014).
[cited by applicant]
Lu, V. et al., Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes,
[cited by applicant]
Lysaght, A. et al., Proteome of human perilymph,
[cited by applicant]
MacCallum, R.M et al., Antibody-antigen interactions: contact analysis and binding site topography, J. Mol. Biol., 262(5):732-745 (1996).
[cited by applicant]
MacKeith, S. et al., Trends in acoustic neuroma management: a 20-year review of the oxford skull base clinic,
[cited by applicant]
Magari, S. et al., Pharmacologic control of a humanized gene therapy system implanted into nude mice, J Clin Invest., 100(11):2865-2872 (1997).
[cited by applicant]
Mahmud, M. et al., Histopathology of the inner ear in unoperated acoustic neuroma,
[cited by applicant]
Maier, P. et al., Retroviral vectors for gene therapy, Future Microbiol., 5(10):1507-1523 (2010).
[cited by applicant]
Manley, Geoffrey A., Comparative auditory neuroscience: understanding the evolution and function of ears,
[cited by applicant]
Mattion, N. et al., Foot-and-mouth disease virus 2A protease mediates cleavage in attenuated Sabin 3 poliovirus vectors engineered for delivery of foreign antigens, J Virol., 70(11):8124-8127 (1996).
[cited by applicant]
McClatchey, A. et al., Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors,
[cited by applicant]
McClatchey, A. et al., The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation,
[cited by applicant]
Miyazaki, J. et al., Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5,
[cited by applicant]
Morrison, S. et al., Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains, Proc Natl Acad Sci USA, 81(21):6851-6855 (1984).
[cited by applicant]
Mujic-Delic, A. et al., GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics, Trends Pharmacol Sci., 35(5):247-255 (2014).
[cited by applicant]
Murillo, O. et al., Liver expression of a miniATP7B gene results in long-term restoration of copper homeostasis in a Wilson disease model in mice,
[cited by applicant]
Muyldermans, S. et al., Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains, Trends Biochem Sci., 26(4):230-235 (2001).
[cited by applicant]
Muyldermans, S., Nanobodies: natural single-domain antibodies, Ann. Rev. Biochem. 82:775-797 (2013).
[cited by applicant]
Muyldermans, S., Single domain camel antibodies: current status, J. Biotechnol., 74(4):277-302 (2001).
[cited by applicant]
Muzyczka, N., Use of adeno-associated virus as a general transduction vector for mammalian cells, Curr Top Microbiol Immunol, 158:97-129 (1992).
[cited by applicant]
Naganawa, S. et al., Endolympathic hydrops in patients with vestibular schwannoma: visualization by non-contrast-enhanced 3D FLAIR,
[cited by applicant]
Niwa, H. et al., Efficient selection for high-expression transfectants with a novel eukaryotic vector,
[cited by applicant]
No Author Listed, High-dose AAV gene therapy deaths,
[cited by applicant]
No, D. et al., Ecdysone-inducible gene expression in mammalian cells and transgenic mice, Proc Natl Acad Sci USA, 93(8):3346-3351 (1996).
[cited by applicant]
Nuttall, A. et al., Acute perilymphatic perfusion of the guinea pig cochlea,
[cited by applicant]
Omichi, R. et al., Hair cell transduction efficiency of single- and dual-AAV serotypes in adult murine cochleae,
[cited by applicant]
Orban, T. et al., Applying a “double-feature” promoter to identify cardiomyocytes differentiated from human embryonic stem cells following transposon-based gene delivery,
[cited by applicant]
Orkin, S. et al., Thalassemia due to a mutation in the cleavage-polyadenylation signal of the human beta-globin gene, EMBO J., 4(2):453-456 (1985).
[cited by applicant]
Ostrom, Q. et al., CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015,
[cited by applicant]
Paldor, I. et al., Growth rate of vestibular schwannoma,
[cited by applicant]
Pan, B. et al., Gene therapy restores auditory and vestibular function in a mouse model of Usher syndrome type 1c,
[cited by applicant]
Papadopoulos, N. et al., Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab,
[cited by applicant]
Pararas, E. et al., Kinetics of reciprocating drug delivery to the inner ear,
[cited by applicant]
Parente, V. and Corti, S., Advances in spinal muscular atrophy therapeutics,
[cited by applicant]
Pedrosa, C. et al., Determinants and impact of headache after acoustic neuroma surgery,
[cited by applicant]
Pelletier, J. et al., Cap-independent translation of poliovirus mRNA is conferred by sequence elements within the 5′ noncoding region., Mol. Cell. Biol. 8(3):1103-1112 (1988).
[cited by applicant]
Peris-Celda, M. et al., Main symptom that led to medical evaluation and diagnosis of vestibular schwannoma and patient-reported tumor size: cross-sectional study in 1,304 patients,
[cited by applicant]
Peyre, M. et al., Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results,
[cited by applicant]
Piccioli, P. et al., Neuroantibodies: ectopic expression of a recombinant anti-substance P antibody in the central nervous system of transgenic mice, Neuron, 15(2):373-384 (1995).
[cited by applicant]
Piccioli, P. et al., Neuroantibodies: molecular cloning of a monoclonal antibody against substance P for expression in the central nervous system, Proc Natl Acad Sci USA, 88(13):5611-5615 (1991).
[cited by applicant]
Plotkin, S. et al., Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients, Otol Neurotol., 33(6):1046-1052 (2012).
[cited by applicant]
Plotkin, S. et al., Hearing improvement after bevacizumab in patients with neurofibromatosis type 2,
[cited by applicant]
Plotkin, S. et al., Multicenter, prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma,
[cited by applicant]
Poulin, K. et al., Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX, J Virol., 84(19):10074-10086 (2010).
[cited by applicant]
Proudfoot, N. et al., Integrating mRNA processing with transcription, Cell, 108(4):501-512 (2002).
[cited by applicant]
Pryadkina, M. et al., A Comparison of AAV Strategies Distinguishes Overlapping Vectors for Efficient Systemic Delivery of the 6.2 Kb Dysferlin Coding Sequence, Meth. Clin. Devel. 2:15009 (2015).
[cited by applicant]
Quesnel, A. et al., Otosclerosis: temporal bone pathology,
[cited by applicant]
Rahbarizadeh, F. et al., Nanobody; an old concept and new vehicle for immunotargeting, Immunol Invest., 40(3):299-338 (2011).
[cited by applicant]
Rask-Andersen, H. et al., Perilymph/modiolar communication routes in the human cochlea,
[cited by applicant]
Reid, C. et al., Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD, Scientific Reports, 8(1): p. 11763 (2018).
[cited by applicant]
Remenschneider, A. et al., Is the cause of sensorineural hearing loss in patients with facial schwannomas multifactorial?,
[cited by applicant]
Reznitsky, M. et al., Epidemiology of vestibular schwannomas—prospective 40-year data from an unselected national cohort,
[cited by applicant]
Roesch, S. et al., Functional Testing of SLC26A4 Variants-Clinical and Molecular Analysis of a Cohort with Enlarged Vestibular Aqueduct from Austria, Int. J. Mol. Sci. 19(1):209 (2018).
[cited by applicant]
Ronzitti, G. et al., Human immune responses to adeno-associated virus (AAV) Vectors,
[cited by applicant]
Roosli, C. et al., Dysfunction of the cochlea contributing to hearing loss in acoustic neuromas: an underappreciated entity,
[cited by applicant]
Rozema, D. et al., Dymanic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes, Proc Natl Acad Sci USA, 104(32):12982-12987 (2007).
[cited by applicant]
Rudikoff, S. et al., Single amino acid substitution altering antigen-binding specificity, Proc. Natl. Acad. Sci. USA, 79:1979-1983 (1982).
[cited by applicant]
Russell, S. et al., Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial,
[cited by applicant]
Ryan, A. et al., Cellular targeting for cochlear gene therapy, Adv Otorhinolaryngol., 66:99-115 (2009).
[cited by applicant]